Skip to main content

GlaxoSmithKline plc (GSK)

NYSE: GSK · Delayed Price · USD
39.50
-0.05 (-0.13%)
After-hours:Oct 21, 2021 5:04 PM EDT
39.55
0.09 (0.23%)
At close: Oct 21, 4:00 PM
Market Cap99.28B
Revenue (ttm)45.37B
Net Income (ttm)6.05B
Shares Out2.52B
EPS (ttm)2.39
PE Ratio16.58
Forward PE12.41
Dividend$2.15 (5.44%)
Ex-Dividend DateAug 19, 2021
Volume5,206,519
Open39.38
Previous Close39.46
Day's Range39.28 - 39.56
52-Week Range31.43 - 42.14
Beta0.39
AnalystsBuy
Price Target48.08 (+21.6%)
Est. Earnings DateOct 27, 2021

About GSK

GlaxoSmithKline plc, together with its subsidiaries, engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, HIV, immuno-inflammation, oncology, ...

IndustryPharmaceuticals
Founded1715
CEOEmma Walmsley
Employees94,066
Stock ExchangeNYSE
Ticker SymbolGSK
Full Company Profile

Financial Performance

In 2020, GSK's revenue was 34.10 billion, an increase of 1.02% compared to the previous year's 33.75 billion. Earnings were 5.75 billion, an increase of 23.77%.

Financial numbers in millions GBPFinancial Statements

Analyst Forecast

According to 6 analysts, the average rating for GSK stock is "Buy." The 12-month stock price forecast is 48.08, which is an increase of 21.58% from the latest price.

Price Target
$48.08
(21.58% upside)
Analyst Consensus: Buy

News

3 Top Stocks You Can Still Buy for Under $20 a Share

These three companies are in the early stages of revolutionizing their specific industries.

Other symbols:LTCHSOFI
6 days ago - The Motley Fool

Glaxo Should Consider Buying a Headache (Company), Says Industry Consultant

Drug consulting group Evaluate thinks GlaxoSmithKline PLC ( GSK , Financial) should consider making a run at Biohaven Pharmaceutical Holding Company Ltd. ( BHVN , Financial) after the latter recorded ou...

1 week ago - GuruFocus

GSK or NVO: Which Is the Better Value Stock Right Now?

GSK vs. NVO: Which Stock Is the Better Value Option?

1 week ago - Zacks Investment Research

Is GlaxoSmithKline (GSK) Stock Undervalued Right Now?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest v...

1 week ago - Zacks Investment Research

GSK on track with consumer split as buyout report boosts shares

GlaxoSmithKline is "firmly on track" to spin off its consumer health business next year, the British drugmaker said on Tuesday, after Bloomberg News reported the unit could attract bids from private equ...

1 week ago - Reuters

2 Stocks Set to Win From the Historic Malaria Vaccine Approval

But those wins probably won't be all that big.

Other symbols:AGEN
1 week ago - The Motley Fool

GSK to cement split with two new headquarters

GlaxoSmithKline on Monday laid out plans for a new, 120 million pound ($164 million) headquarters for its soon-to-be-independent consumer healthcare business and also said its remaining pharmaceuticals ...

1 week ago - Reuters

Here's Why 2022 Could Be a Huge Year for GlaxoSmithKline

Another big step in preventing HIV and AIDS has been taken and GlaxoSmithKline is at the forefront.

1 week ago - The Motley Fool

Glaxo (GSK) Eyes Nod for Triumeq Expanded Use in Pediatric HIV

Glaxo (GSK) seeks approval for a new dispersible single-tablet regimen containing dolutegravir to treat children living with HIV.

2 weeks ago - Zacks Investment Research

9 Big Pharmaceutical Stocks Sporting Stellar Yields

Large-cap pharmaceutical stocks offer investors stable, substantial dividends, regardless of market conditions. Here are nine that stand out.

2 weeks ago - Kiplinger

Here's a High-Yield Dividend Stock Wall Street Thinks Could Jump 26% Within 12 Months

There's plenty to like with this big pharma stock -- but a few problem spots, too.

Other symbols:SNY
2 weeks ago - The Motley Fool

GlaxoSmithKline, Merck KGaA End $4B Cancer Drug Pact

Merck KGaA (OTC: MKGAF) and GlaxoSmithKline Plc (NASDAQ: GSK) have ended their $4 billion collaboration on cancer treatment, bintrafusp alfa. Merck said the move was a mutual decision, primarily due to ...

Other symbols:MRK
3 weeks ago - Benzinga

3 Big Drug/Biotech Stocks to Boost Your Portfolio's Health

Sanofi (SNY), Pfizer (PFE) and Novo Nordisk (NVO) are three large drugmakers that are worth betting on in the current scenario.

Other symbols:BNTXKDMNNVOPFESNY
3 weeks ago - Zacks Investment Research

Merck Announces Mutual Decision to End Bintrafusp Alfa Agreement With GSK

DARMSTADT, Germany--(BUSINESS WIRE)--Merck, a leading science and technology company, today announced a mutual decision with GSK to terminate their agreement on bintrafusp alfa, effective September 30, ...

Other symbols:MRK
3 weeks ago - Business Wire

Glaxo's (GSK) Long-Acting Drug NDA Gets Priority Tag for PrEP

Glaxo's (GSK) HIV subsidiary, ViiV Healthcare gets FDA's priority review for a new drug application for long-acting cabotegravir regimen. ViiV Healthcare signs a deal for developing ultra long-acting HI...

3 weeks ago - Zacks Investment Research

ViiV Healthcare's Dovato Combo Regime Shows Encouraging Long Term Data In HIV Patients

ViiV Healthcare, a joint venture between GlaxoSmithKline plc (NYSE: GSK), Pfizer Inc (NYSE: PFE), and Shionogi,  presented three-year results from the TANGO study at IDWeek 2021. Phase 3 TANGO study ass...

Other symbols:PFE
3 weeks ago - Benzinga

GSK, Pfizer Backed Long-Acting HIV Med Under FDA Priority Review As Preventative Option

The FDA has accepted and granted Priority Review to ViiV Healthcare's marketing application seeking approval for injectable cabotegravir long-acting for pre-exposure prophylaxis (PrEP). The priority rev...

Other symbols:PFE
3 weeks ago - Benzinga

Sensodyne® Repair and Protect with Deep Repair is Proud to Deliver a Minty & Whitening Toothpaste, Just in Time for N...

WARREN, N.J., Sept. 28, 2021 /PRNewswire/ -- GSK Consumer Healthcare (LSE/NYSE: GSK) is raising a cup – or two – of coffee to celebrate enjoying life's simple pleasures without the interruption of tooth...

3 weeks ago - PRNewsWire

Glaxo - Vir Biotech's COVID Treatment Approved In Japan

Japan's health ministry expert committee has approved GlaxoSmithKline Plc (NYSE: GSK) - Vir Biotechnology Inc's (NASDAQ: VIR) sotrovimab, a COVID-19 antibody therapy. Related Link:   GSK - Vir Biotech's...

Other symbols:VIR
3 weeks ago - Benzinga

Activist investor Bluebell takes stake in GSK - FT

Activist investor Bluebell Capital Partners has taken a small stake in British pharmaceuticals group GlaxoSmithKline in efforts to shake up top management, a Financial Times report said on Wednesday.

4 weeks ago - Reuters

Glaxo's (GSK) Nucala Gets CHMP Nod for 3 Diseases in Europe

Glaxo (GSK) is seeking approval of Nucala for hypereosinophilic syndrome, eosinophilic granulomatosis with polyangiitis) and chronic rhinosinusitis with nasal polyps in Europe

1 month ago - Zacks Investment Research

5 COVID Vaccine Stocks With Late-Stage Candidates You'll Want to Watch

Their vaccines could be late to the party. But the stocks might still be big winners.

Other symbols:DVAXINONVAXSNY
1 month ago - The Motley Fool

GSK teams with King's College to use AI to fight cancer

Artificial intelligence will be used to develop personalised treatments while investigating role of genetics

1 month ago - The Guardian

A Look at R&D Spending in Pharma

In GAAP accounting, fixed assets are usually capitalized on a company's balance sheet and subsequently amortized over their expected useful life.

Other symbols:AZNJNJMRKNVSPFE
1 month ago - GuruFocus

Glaxo, Pfizer, J&J and Sanofi Expected to Grab Biggest Shares of RSV Vaccine Business

GlaxoSmithKline PLC ( GSK , Financial) is forecasted to carve out more than 25% of a vaccine market that is expected to reach $10.5 billion by 2030. FiercePharma repotrted three other members of big pha...

Other symbols:JNJPFESNY
1 month ago - GuruFocus